$20 party, page-29

The results and response will be particularly interesting considering the large number of efficacy measures being assessed. A broad range of possible outcomes can occur with headline announcements anything like "statistically significant improvement in all measures" at one end and "safe and well tolerated" (with no reference to efficacy because there was basically none) at the other. Many possibilities exist in between and how Neuren present what plays out and the market receives it will have a huge impact on the short-term share price. The company has learnt a lot from working with Retts so they should have strategised this extensively but it's still ultimately in the hands of biology and its vagaries. They are certainly likely to be confident based on the common ground in how Trof and 2591 operate, we will see.

I do think the way Daybue is rolling out then the current valuation is still low regardless and if there is a drop it will recover as royalties and milestones keep the cash coming in but obviously we're hoping for the other scenario. Excited for the big announcement!